Blog
RSS FeedPosted by Michael Wonder on 20 Sep 2019
SanBio granted regenerative medicine advanced therapy designation from the U.S. FDA for SB623 for the treatment of chronic neurological motor deficits secondary to traumatic brain injury
19 September 2019 - The SanBio Group today announced that the U.S. FDA has granted regenerative medicine advanced therapy designation ...
Posted by Michael Wonder on 11 Sep 2019
Immunotherapy a groundbreaking new cancer treatment, but prohibitively expensive
10 September 2019 - Dave Roberts is fighting for his life, and his doctor says there is only one option ...
Posted by Michael Wonder on 27 Aug 2019
DiscGenics receives FDA fast track designation for disc degeneration cell therapy
26 August 2019 - DiscGenics today announced that the U.S. FDA has granted Fast Track designation for its investigational cell ...
Posted by Michael Wonder on 18 Aug 2019
Cancer patient David Downs working to bring treatment that helped him to NZ
18 August 2019 - There are those people who cheerfully refer to themselves as glass half-full types – and then ...
Posted by Michael Wonder on 07 Aug 2019
Trump Administration makes CAR T-Cell cancer therapy available to Medicare beneficiaries nationwide
7 August 2019 - Decision ensures consistency in access to the innovative new cancer therapy, and CMS is working closely ...
Posted by Michael Wonder on 06 Aug 2019
ICER seeks public comment on proposed methods adaptations for assessments of potential cures and other transformative therapies
6 August 2019 - Proposed adaptations help manage increased uncertainty, capture new value dimensions for appraisal committee voting, and adopt a ...
Posted by Michael Wonder on 04 Aug 2019
Melbourne to pioneer free treatment to save sickest cancer kids
4 August 2019 - The nation’s youngest cancer patients, who had previously been forced to travel overseas for lifesaving treatment, will ...
Posted by Michael Wonder on 01 Aug 2019
Expensive Gilead, Novartis cancer therapies losing patients to experimental treatments
30 July 2019 - Unusually high numbers of U.S. lymphoma patients are choosing experimental treatments over expensive cell therapies sold by ...
Posted by Michael Wonder on 30 Jul 2019
CAR T-cell therapy: a microcosm for the challenges ahead in Medicare
29 July 2019 - The search for more effective and less toxic therapies for cancer has occupied scientists for decades. ...
Posted by Michael Wonder on 16 Jul 2019
Caladrius Biosciences receives advanced therapy medicinal product classification for CLBS12, its CD34+ cell therapy for critical limb ischaemia
15 July 2019 - Caladrius Biosciences announced today that the EMA has granted Advanced Therapy Medicinal Product classification to the Company’s ...
Posted by Michael Wonder on 02 Jul 2019
Innovation prizes to support cell and gene therapy
2 July 2019 - Personalised cell and gene therapy represent a fundamental therapeutic revolution. ...
Posted by Michael Wonder on 25 Jun 2019
Health economic assessment of Kymriah in diffuse large B-cell lymphoma
20 June 2019 - TLV has produced a health economic knowledge base for county councils for CAR-T cell treatment Kymriah ...
Posted by Michael Wonder on 19 Jun 2019
FDA grants fast track designation for Torque's first deep-primed T cell cancer immunotherapy program, TRQ-1501
18 June 2019 - Torque announced today that the U.S. FDA granted fast track designation for Torque's first Deep-Primed T cell ...
Posted by Michael Wonder on 05 Jun 2019
Paying for CAR-T therapy amidst limited health system resources
3 June 2019 - CAR-T is paving a new path toward achieving access and reimbursement within limited health-system resources. How do ...
Posted by Michael Wonder on 30 May 2019
Mesoblast initiates rolling submission of biologics license application to U.S. FDA for remestemcel-L in the treatment of acute graft versus host disease
30 May 2019 - Mesoblast today announced that it has filed the first component of a rolling submission for a biologics ...